DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Biotechnology

Healthcare
$8.59 -0.17%

-$0.01 today

Market cap
$463.49M
Beta
1.00
P/E (TTM)
-8.8
EPS (TTM)
-$0.65
52W Low $3.48High $10.42

Volume 0.21M

Average 0.19M

DMAC Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

DiaMedica Therapeutics Inc.NASDAQ: DMAC

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 53.79M shares rose 25.6% year over year, ahead of the +16.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 14.5% from the prior quarter. Over 3 fiscal years it compounded at +21.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +25.6% holds above the trailing-twelve-month pace of +16.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
53.79M+14.5% QoQ
Last fiscal yearDec 2025
46.98M+16.3% YoY
LTMMar 2026
48.34M+16.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+25.6%——
1 year+16.3%——
3-year CAGR+21.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
46.98M USD
Year-over-year change
+16.3%
4-year CAGR
+22.6%

Weighted Avg Shares vs competitors

How DMAC compares with its peers on the latest reported figures

  • DMAC's LTM Mar 2026 weighted avg shares of 48.34M shares is the 5th highest of the 7 companies compared; the peer median is 121.37M shares.
  • Its year-over-year change of +16.1% is the 4th highest of 7, against a peer median of +12.7%.
  • Over three fiscal years its annual growth of +21.1% compares with a peer median of +11.9%.
DMAC Competitors Peer median
Weighted Avg Shares for DMAC and competitors
Company Period LTM YoY 3-year CAGR
AKBAAkebia Therapeutics, Inc.LTM Mar 2026264.94M +21.2%+12.1%
DNLIDenali Therapeutics Inc.LTM Jun 2026180.46M +5.8%+11.8%
PROKProKidney Corp.LTM Mar 2026135.66M +18.2%+29.6%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026107.08M +1278.7%+372.5%
DMACDiaMedica Therapeutics Inc.LTM Mar 202648.34M +16.1%+21.1%
MAZEMaze Therapeutics, Inc.LTM Mar 202646.63M +6.5%-0.6%
BIOABioAge Labs, Inc.LTM Mar 202637.57M +7.3%+1.7%
Peer median (excluding DMAC) 121.37M+12.7%+11.9%

Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.77M7.84M13.11M19.06M24.61M
Selling, General & Admin4.88M6.16M8.16M7.62M9.78M
Operating Expenses13.65M14M21.27M26.68M34.4M
Depreciation & Amortization24K25K30K39K43K
EBITDA(13.54M)(13.62M)(19.31M)(24.38M)(32.7M)
EBITDA Margin—————
Operating Income(13.65M)(14M)(21.27M)(26.68M)(34.4M)
Operating Margin—————
Interest Income0002.3M0
Interest Expense00000
Other Income / Expenses82K353K1.93M2.27M1.66M
Income Before Tax(13.56M)(13.65M)(19.34M)(24.41M)(32.74M)
Pre-Tax Margin—————
Income Tax Expense28K28K43K30K28K
Net Income(13.59M)(13.68M)(19.38M)(24.44M)(32.77M)
Net Margin—————
EPS (Basic)(0.65)(0.52)(0.60)(0.60)(0.70)
EPS (Diluted)(0.65)(0.52)(0.60)(0.60)(0.70)
Weighted Avg Shares20.77M26.44M32.57M40.4M46.98M
Weighted Avg Shares (Diluted)20.77M26.44M32.57M40.4M46.98M

DiaMedica Therapeutics Inc.

NASDAQ:DMAC

Intrinsic Alpha fair value

Locked

Current Price

$8.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.